Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q9BRK3

UPID:
MXRA8_HUMAN

ALTERNATIVE NAMES:
Limitrin

ALTERNATIVE UPACC:
Q9BRK3; B3KTR6; B4DE34; Q5TA39; Q96KC3

BACKGROUND:
Limitrin, or Matrix remodeling-associated protein 8, is integral to cell signaling, osteoclastogenesis inhibition, chondrocyte proliferation, and angiogenesis suppression. It functions by attenuating integrin ITGB3 signaling and enhancing hedgehog pathway expression in chondrocytes. Additionally, it serves as a receptor for arthritogenic alphaviruses, contributing to their pathogenesis.

THERAPEUTIC SIGNIFICANCE:
Exploring the functionalities of Limitrin opens up avenues for novel therapeutic interventions. Its role in regulating key biological processes such as cell migration, apoptosis in endothelial cells, and signaling pathways offers insights into developing treatments for diseases related to bone remodeling, cartilage formation, and vascular disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.